<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01335581</url>
  </required_header>
  <id_info>
    <org_study_id>C69-10-M</org_study_id>
    <nct_id>NCT01335581</nct_id>
  </id_info>
  <brief_title>Study of Laser Treatment of Melasma</brief_title>
  <official_title>A Study of the RevLite Q-Switched Nd:YAG Laser System With Smart Infinite (SI) Handpiece for the Treatment of Refractory Mixed Type Melasma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ConBio, a Cynosure Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cynosure, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the RevLite laser in the treatment of refractory&#xD;
      mixed type melasma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Melasma Area Severity Assessment (MASI)</measure>
    <time_frame>3 Months</time_frame>
    <description>The severity of the melasma is assessed based on a photographic scale. The scale ranges from 0 to 48, with 48 being the most severe.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Refractory Mixed Type Melasma</condition>
  <arm_group>
    <arm_group_label>Laser treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laser treatment added to microdermabrasion and topical lightening agent regimen</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Q-Switched Nd:YAG Laser (RevLite)</intervention_name>
    <description>Laser treatment added to a microdermabrasion and topical lightening agent regimen</description>
    <arm_group_label>Laser treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fitzpatrick Skin Type III-VI&#xD;
&#xD;
          -  mixed (epidermal and dermal) melasma diagnosed by Wood's Lamp exam&#xD;
&#xD;
          -  age 18 or older&#xD;
&#xD;
          -  melasma persisting for greater than 6 months that has failed to respond to&#xD;
             conventional treatment with hydroquinone or other topical lightening agents&#xD;
&#xD;
          -  written and verbal informed consent&#xD;
&#xD;
          -  willing and able to comply with study instructions and return to the clinic for&#xD;
             required visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, breastfeeding, taking birth control pills or plans to become pregnant&#xD;
             during the study&#xD;
&#xD;
          -  history of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins&#xD;
             or photodermatosis&#xD;
&#xD;
          -  any skin pathology or condition that could interfere with the evaluation or requires&#xD;
             the use of interfering topical or systemic therapy&#xD;
&#xD;
          -  uncorrected coagulation defect or is currently using anti-coagulation medication&#xD;
             (including but not limited to heavy aspirin therapy)&#xD;
&#xD;
          -  any condition which, in the investigator's opinion, would make it unsafe for the&#xD;
             subject to participate in this research study&#xD;
&#xD;
          -  currently enrolled in an investigational drug or device trial, or has received an&#xD;
             investigational drug or has been treated with an investigational device within 30 days&#xD;
             prior to entering this study&#xD;
&#xD;
          -  inability to communicate or cooperate with the investigator due to language problems,&#xD;
             poor mental development, or impaired cerebral function&#xD;
&#xD;
          -  unreliability for the study (this includes subjects who engage in excessive alcohol&#xD;
             intake or drug abuse, or subjects who are unable to return for scheduled follow-up&#xD;
             visits)&#xD;
&#xD;
          -  use of photosensitizing drugs within a timeframe where photosensitization from these&#xD;
             drugs may still be present&#xD;
&#xD;
          -  need to be exposed to artificial tanning devices or excessive sunlight during the&#xD;
             trial&#xD;
&#xD;
          -  Diabetes Type I or II&#xD;
&#xD;
          -  sensitivity to hydroquinone or Retin-A&#xD;
&#xD;
          -  evidence of a compromised immune system or hepatitis&#xD;
&#xD;
          -  use of bleaching creams or retinoids within the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arielle Kauvar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Laser and Skin Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Laser and Skin Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 12, 2011</study_first_submitted>
  <study_first_submitted_qc>April 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2011</study_first_posted>
  <results_first_submitted>October 30, 2020</results_first_submitted>
  <results_first_submitted_qc>December 2, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 28, 2020</results_first_posted>
  <last_update_submitted>December 28, 2020</last_update_submitted>
  <last_update_submitted_qc>December 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Laser Treatment</title>
          <description>Laser treatment added to microdermabrasion and topical lightening agent regimen&#xD;
Q-Switched Nd:YAG Laser (RevLite): Laser treatment added to a microdermabrasion and topical lightening agent regimen</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Laser Treatment</title>
          <description>Laser treatment added to microdermabrasion and topical lightening agent regimen&#xD;
Q-Switched Nd:YAG Laser (RevLite): Laser treatment added to a microdermabrasion and topical lightening agent regimen</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/Ethnicity</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Spanish/Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Indian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian-American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Score</title>
          <description>The Fitzpatrick Skin Score is used to determine skin color. It is a numerical system that classifies skin into six types (Type I, Type II, Type III, Type IV, Type V and Type VI) based on the numerical score achieved (ranging from 0 to 36). The lower the score (and skin type number), the fairer the skin. The higher the score (and skin type number), the more deeply pigmented the skin is.&#xD;
The scale comes from this source:&#xD;
Gupta, Sharma. Skin typing: Fitzpatrick grading and others. Clinics in Dermatology. 2019;37(5):430-436. doi:10.1016/j.clindermatol.2019.07.010</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Fitzpatrick Skin Type I</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Type II</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Type III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Type IV</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Type V</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fitzpatrick Skin Type VI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Melasma Area Severity Assessment (MASI)</title>
        <description>The severity of the melasma is assessed based on a photographic scale. The scale ranges from 0 to 48, with 48 being the most severe.</description>
        <time_frame>3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Laser Treatment</title>
            <description>Laser treatment added to microdermabrasion and topical lightening agent regimen&#xD;
Q-Switched Nd:YAG Laser (RevLite): Laser treatment added to a microdermabrasion and topical lightening agent regimen</description>
          </group>
        </group_list>
        <measure>
          <title>Melasma Area Severity Assessment (MASI)</title>
          <description>The severity of the melasma is assessed based on a photographic scale. The scale ranges from 0 to 48, with 48 being the most severe.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="8.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events occurring were captured and followed throughout each patient's duration in the study, approximately 11 months.</time_frame>
      <desc>Only 1 subject experienced adverse events during this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Laser Treatment</title>
          <description>Laser treatment added to microdermabrasion and topical lightening agent regimen&#xD;
Q-Switched Nd:YAG Laser (RevLite): Laser treatment added to a microdermabrasion and topical lightening agent regimen</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dryness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The PI cannot disclose confidential or proprietary information until after it becomes generally known or available to the public.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jamie Trimper</name_or_title>
      <organization>Cynosure</organization>
      <phone>800-886-2966</phone>
      <email>jamie.trimper@cynosure.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

